Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line macitentan + tadalafil in newly diagnosed pulmonary arterial hypertension
2015-002078-19Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of macitentan and tadalafil in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Ratio of Week 16 to baseline pulmonary vascular resistance. Started Aug 2015; status: completed.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2015-002078-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002078-19.